Showing results (121-130 of 322) with videos related to

Sort By:
Pageof 33
Cancer Medicine|November 11, 2024
Is Centralisation of Cancer Services Associated With Under-Treatment of Patients With High-Risk Prostate Cancer?-A National Population-Based StudyLu Han, Emily Mayne, Joanna Dodkins, et al.
The Journal of Urology|July 17, 2007
Predictors of histological disease progression in untreated, localized prostate cancerRamachandran Venkitaraman, Andrew Norman, Ruth Woode-Amissah, et al.
European Urology|December 3, 2014
A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancerRamachandran Venkitaraman, David Lorente, Vedang Murthy, et al.
The British Journal of Radiology|April 2, 2019
Realizing the potential of magnetic resonance image guided radiotherapy in gynaecological and rectal cancerIngrid M White, Erica Scurr, Andreas Wetscherek, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2025
Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategiesJennifer Le Guevelou, Thomas Zilli, Federica Ferrario, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2025
Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in EnglandJoanna Dodkins, Adrian Cook, Emily Mayne, et al.
International Journal of Radiation Oncology, Biology, Physics|October 22, 2013
Two-year and lifetime cost-effectiveness of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for head-and-neck cancerRacquel E Kohler, Nathan C Sheets, Stephanie B Wheeler, et al.
Neuroradiology|June 30, 2026
Mobile head CT scanner provides superior image quality compared to conventional stationary CTHenrik Andersson, Björn M Hansen, Emma Hall, et al.
European Urology|October 8, 2024
Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled TrialRobert Huddart, Shaista Hafeez, Clare Griffin, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
Pageof 33